The fact that sorafenib increased necrosis and apoptosis but did not induce cell cycle arrest is indicative that it acts through differs mechanisms such as inactivation of the RAF/MEK/ERK pathway HCC and receptor tyrosine kinases involved in tumor progression and angiogenesis [62]. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.